Literature DB >> 3197744

Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.

A C Keech1, R W Harper, P M Harrison, A Pitt, A J McLean.   

Abstract

Chronic coadministration of oral verapamil with oral atenolol resulted in a variable increase in atenolol steady-state plasma concentrations in a group of 10 patients on chronic maintenance therapy. Individual subjects showed changes in area under the plasma atenolol concentration-time curve (AUC) of more than 100%, however group comparisons did not achieve statistical significance unless normalized for verapamil dose. Renal clearance of atenolol was shown to be decreased by more than 25% in 2 subjects studied using intravenous dosing of atenolol. This interaction is likely to contribute to the documented clinical intolerance of combinations of atenolol and verapamil.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197744     DOI: 10.1007/bf00561365

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Simple extraction of atenolol from urine and its determination by high-performance liquid chromatography.

Authors:  A C Keech; P M Harrison; A J McLean
Journal:  J Chromatogr       Date:  1988-04-08

2.  Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.

Authors:  A C Keech; R W Harper; P M Harrison; A Pitt; A J McLean
Journal:  Am J Cardiol       Date:  1986-09-01       Impact factor: 2.778

3.  Increased serum theophylline concentrations secondary to oral verapamil.

Authors:  T G Burnakis; M Seldon; A D Czaplicki
Journal:  Clin Pharm       Date:  1983 Sep-Oct

4.  Dose-dependence of atenolol-ampicillin interaction.

Authors:  A J McLean; A Tonkin; P McCarthy; P Harrison
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

5.  Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.

Authors:  A J McLean; R Knight; P M Harrison; R W Harper
Journal:  Am J Cardiol       Date:  1985-06-01       Impact factor: 2.778

6.  Simple and rapid analysis of atenolol and metoprolol in plasma using solid-phase extraction and high-performance liquid chromatography.

Authors:  P M Harrison; A M Tonkin; A J McLean
Journal:  J Chromatogr       Date:  1985-05-03

7.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

8.  Atenolol interaction with aspirin, allopurinol, and ampicillin.

Authors:  M Schäfer-Korting; W Kirch; T Axthelm; H Köhler; E Mutschler
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

9.  Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.

Authors:  J C McGourty; J H Silas; S A Solomon
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

10.  Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.

Authors:  G J Macphee; G T McInnes; G G Thompson; M J Brodie
Journal:  Lancet       Date:  1986-03-29       Impact factor: 79.321

View more
  5 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.